Trial Profile
A phase I study to determine the pharmacokinetic of carbidopa [Lodosyn] alone and in combination with XP 21279 under fed and fasted conditions compared with levodopa/carbidopa [Sinemet] in volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Mar 2008
Price :
$35
*
At a glance
- Drugs XP 21279 (Primary) ; Carbidopa; Levodopa/carbidopa
- Indications Parkinson's disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors XenoPort
- 13 Mar 2008 Status changed from initiated to completed, based on results reported in a XenoPort media release.
- 07 Jan 2008 New trial record.